This report provides a summary of the status and near-term
plans of the International Vaccine Institute. The perspective
is to the end of 2002, when the IVI's new 17,000 square meter
headquarters building will be ready for occupancy.
During 2000 and early 2001, the IVI has become a functioning
international center of research, training and technical assistance
for vaccines needed in developing countries. It has continued
and expanded :
•
|
The creation of a multinational team of scientists and
technical specialists in clinical research, product development,
technical assistance, and training at its headquarters
in Seoul and in sites in various developing countries.
|
| • |
The formation of collaborative networks throughout Asia
and elsewhere for multi-disciplinary studies of vaccines. |
•
|
The development of a multi-country, multidisciplinary
program to accelerate the development and introduction
of vaccines against the enteric infections cholera, Shigella,
and typhoid fever. |
•
|
The measurement of the disease burden in Asian children
of meningitis caused by Haemophilus influenzae type b
(Hib), Neisseria meningitidis, and Streptococcus pneumoniae.
|
•
|
The development of a multi-country, multidisciplinary
program on Japanese encephalitis to expand the use of
existing vaccines and accelerate the development of new
vaccines. |
•
|
The provision of technical assistance and training programs
for vaccine production and regulation in
developing countries. |
•
|
The formation of collaborative networks with vaccine
manufacturers in developed and developing countries to
accelerate vaccine research, development and technology
transfer. |
| • |
The provision of training in the clinical evaluation
of vaccines in developing country settings. |
| • |
The formation of close collaborations with WHO and GAVI
in undertaking needed vaccine-related activities. |
•
|
The construction of a major research building
with a pilot production plant at the site of the IVI
headquarters in Seoul, Korea with completion expected
by the end of 2002. |
Plaque at the IVI temporary facilities
at Seoul National University
The year 2000 was a period of rapid growth in the programs,
staffing, and funding of the IVI. This growth vibrantly illustrates
the potential of an international research center devoted
to vaccines against diseases of special concern in developing
countries.
Dr. Wu Jinggui; Dr. Tao Fangbiao; Dr. XiaBangliang; Dr. Lorenz
von Seidlein(IVI staff member);
Dr. Du Lin; and Dr. Song Xiao Bo in front of the Magang Hospital
of the Maanshan Steel Trust Hospital
, Anhui province, China, an IVI vaccine trial and surveillance
site.
Inaugural meeting of the Board of Trustees, October 1997
|
